daklinza daclatasvir (as dihyrochloride) 60 mg tablet blister
bristol-myers squibb australia pty ltd - daclatasvir dihydrochloride -
sprycel dasatinib 100 mg tablet bottle
bristol-myers squibb australia pty ltd - dasatinib, quantity: 100 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; croscarmellose sodium; magnesium stearate; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.
sprycel dasatinib 70 mg tablet bottle
bristol-myers squibb australia pty ltd - dasatinib, quantity: 70 mg - tablet, film coated - excipient ingredients: croscarmellose sodium; microcrystalline cellulose; magnesium stearate; hyprolose; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.
sprycel dasatinib 50 mg tablet bottle
bristol-myers squibb australia pty ltd - dasatinib, quantity: 50 mg - tablet, film coated - excipient ingredients: magnesium stearate; hyprolose; microcrystalline cellulose; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.
sprycel dasatinib 20 mg tablet bottle
bristol-myers squibb australia pty ltd - dasatinib, quantity: 20 mg - tablet, film coated - excipient ingredients: hyprolose; microcrystalline cellulose; magnesium stearate; croscarmellose sodium; lactose monohydrate; titanium dioxide; hypromellose; macrogol 400 - sprycel is indicated for the treatment of adults aged 18 years or over with: - newly diagnosed philadelphia chromosome positive (ph+) chronic myeloid leukaemia in the chronic phase. - chronic, accelerated or myeloid or lymphoid blast phase chronic myeloid leukameia with resistance or intolerance to prior therapy including imatinib. - newly diagnosed philadelphia chromosome positive acute lymphoblastic leukameia integrated with chemotherapy. - philadelphia chromosome positive acute lymphoblastic leukamia with resistance or intolerance to prior therapy.,sprycel is indicated for the treatment of paediatric patients with: - ph+ cml in the chronic phase. - newly diagnosed ph+ all in combination with chemotherapy.
eliquis
bristol-myers squibb australia pty ltd - apixaban -
revia
bristol-myers squibb australia pty ltd - naltrexone hydrochloride -
monoplus
bristol-myers squibb australia pty ltd - fosinopril sodium; hydrochlorothiazide -
yervoy
bristol-myers squibb australia pty ltd - ipilimumab -
bydureon
bristol-myers squibb australia pty ltd - exenatide -